PHILADELPHIA, July 19, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB), an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders, and Max Neeman International, one of the leading and largest clinical research organizations (“CROs”) in India, jointly announce that the collaborative Phase II clinical research effort for one of Hemispherx’ flagship products, Alferon N Injection® (interferon Alfa-n3) was approved by the Indian Drugs Controller General on July 13, 2010 and is expected to start enrolling patients right away.
